Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

6.545 -0.055 (-0.83%)
Streaming Delayed Price Updated: 1:22 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
32 33 Next >
Psychedelic Compounds-Based Stocks Continue To Decline
Our index tracks 6 of the largest clinical-stage startups, which have an average market capitalization of $65.5M and an average stock price of $0.69/share. 
Via Talk Markets
Psychedelic Stock Gainers And Losers From May 26, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 21.06% at $0.34 
Via Benzinga
TripAdvisor, Seelos Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: TripAdvisor (NASDAQ:TRIP) shares closed up 6.06% at $23.45 
Via Benzinga
Psyched: Medical Psychedelics In Davos, Canadian Sen Does Psychedelics, Ei.Ventures & Mycotopia To Merge Into $383M Company
Medical Psychedelics have made it into Davos, just in time for the World Economic Forum. 
Via Benzinga
Mind Medicine: Q1 Earnings Insights
Mind Medicine (NASDAQ:MNMD) reported its Q1 earnings results on Monday, May 16, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For May 16, 2022
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand. 
Via Benzinga
Psychedelic Stock Gainers And Losers From May 24, 2022
GAINERS: LOSERS: Cybin (AMEX:CYBN) shares closed down 9.99% at $0.61 
Via Benzinga
Cannabis Movers & Shakers: Mind Medicine, 22nd Century Group, Grown Rogue International
Mind Medicine Names New CEO Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) has hired Schond L. Greenway to oversee its finance department. 
Via Benzinga
Cybin, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Cybin (AMEX:CYBN) shares closed up 15.60% at $0.68 
Via Benzinga
MindMed Appoints Schond L. Greenway As CFO
Mind Medicine Inc. (NASDAQ: MNMD), (NEO:MMED), a clinical stage bio-pharmaceutical company developing novel products to treat brain health disorders, appointed Schond L. Greenway as CFO. 
Via Benzinga
Psychedelic Stock Gainers And Losers From May 20, 2022
GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 8.33% at $0.77 
Via Benzinga
Revive Therapeutics, Allied Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 21.90% at $0.29 
Via Benzinga
MindMed Reports Promising Results For Non-Hallucinogenic Ibogaine Congener Substance
MindMed Inc. (NASDAQ: MNMD) reported favorable results for one of its proprietary compounds. 
Via Benzinga
Cybin, Allied Among Top Psychedelic Movers Of Today
GAINERS: Cybin (AMEX:CYBN) shares closed up 13.43% at $0.55 
Via Benzinga
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Intelgenx Technologies (OTC:IGXT) shares closed up 16.85% at $0.32 
Via Benzinga
Psyched: Compass, Atai And MindMed Release Q1 Earnings, Phase 3 MDMA Trial Closer To Completion, Enveric Splits Into Two Companies
The psychedelics space got a new glimpse at the financials of some of its heavy hitters with the release of earnings reports for the first quarter of 2022. 
Via Benzinga
Psychedelic Stock Gainers And Losers From May 16, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 25.00% at $0.22 
Via Benzinga
MindMed Reports Financial Results For Q1, With Lower Cash Balance Compared To December Last Year
MindMed (NASDAQ: MNMD) announced its financial results for the first quarter of 2022, which ended March 31. 
Via Benzinga
2 Of The 5 Cannabis Categories Advanced Slightly During Second Week Of May
The cannabis sector consists of 5 distinct categories, each performing differently from the other. Here, the stock performances during the second week of May, YTD and from the 2021 peak. 
Via Talk Markets
Psychedelic Compounds-Based Stocks Index Imploding
Our index of Psychedelic Compounds-Based Drug Stocks tracks clinical-stage startups still in R&D is down 60% YTD; -78% from its 2021 high. 
Via Talk Markets
Field Trip Health, ATAI Life Sciences Among Top Psychedelic Movers Of Today
GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 20.93% at $0.94 
Via Benzinga
Earnings Preview For Mind Medicine
Mind Medicine (NASDAQ:MNMD) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Mind Medicine... 
Via Benzinga
Psychedelic Stock Gainers And Losers From May 12, 2022
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 4.44% at $7.06 
Via Benzinga
Can LSD Treat Anxiety? MindMed's New Topline Data Show Promise, Here's The Research
MindMed (NASDAQ: MNMD) researchers shared topline clinical results for a Phase 2 LSD clinical study at the recent Psych Symposium, which was co-sponsored by University Hospital Basel (UHB). 
Via Benzinga
Psychedelic Stock Gainers And Losers From May 11, 2022
GAINERS: Intelgenx Technologies (OTC:IGXT) shares closed up 1.37% at $0.27 LOSERS: 
Via Benzinga
Intelgenx Technologies, Compass Pathways Among Top Psychedelic Movers Of Today
GAINERS: Intelgenx Technologies (OTC:IGXT) shares closed up 16.68% at $0.26 
Via Benzinga
EXCLUSIVE: Kevin Harrington Becomes The Latest 'Shark Tank' Judge To Enter The Psychedelics Space
The psychedelics industry is quickly becoming the latest playground for celebrity investors and influencers in the financial sphere. Kevin Harrington, one of the original “sharks” in ABC's “Shark Tank”... 
Via Benzinga
Psychedelic Stock Gainers And Losers From May 9, 2022
GAINERS: LOSERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed down 13.47% at $3.34 
Via Benzinga
The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More
Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ:... 
Via Benzinga
Psychedelic Stocks Continue To Decline In May
The 10 companies in our Psychedelic Compounds-Based Drug Stocks Index are clinical-stage startups still in the product research and development of novel compounds with no products and no revenue. 
Via Talk Markets
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.